We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Releases 510(k) Transfer Policy: Clarifies Area Previously in Shadow

FDA Releases 510(k) Transfer Policy: Clarifies Area Previously in Shadow

January 2, 2015

Companies assuming possession of a previously cleared 510(k) device would have 30 days to register the transfer of ownership on an FDA online database, under draft guidance released late last month.

The proposed policy is intended to end long-standing confusion regarding how to track and update the ownership of 510(k)s.

The FDA does not require a new 510(k) when ownership changes. But while companies typically notify the agency when they acquire a cleared device, establishing an historical sequence of transfers for a particular 510(k) has been challenging, the guidance says.

Implementation of the FDA’s Unified Registration and Listing System Device Registration and Listing Module has changed all that, however. An offshoot of the 2007 FDA Amendments Act, FURLS DRLM provides a searchable online database of up-to-date 510(k) information. Devicemakers must register with the database and list the 510(k) numbers for all products they manufacture. When ownership changes hands, the old owner will delist the device and the new one will add its name and information.

If more than one company claims ownership of a 510(k), the FDA will contact all parties involved to determine the rightful owner, according to the guidance. The database will list the last company to enter information as the current owner while the FDA resolves the issue. Court orders, contracts, wills and other historical records may be submitted to support a case of ownership.

Owners of 510(k)s for in vitro diagnostic devices covered under the Clinical Laboratory Improvement Acts should submit updated labeling when the manufacturer or device name changes so that the FDA can ensure the CLIA categorization still applies.

Comments are due Feb. 20 to docket no. FDA-2014-D-1837. View the draft guidance at www.fdanews.com/01-05-15-transfer.pdf. — Elizabeth Orr

Regulatory Affairs Submissions and Approvals

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing